# DNATURE BIO LABS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dnature-bio-labs

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Website: www.dnaturebio.com
- Total disclosed funding: $3M
- Latest round: Series A (Jul 29, 2021)
- Investors on record: 1

## About

Based in Seoul, South Korea, and founded in 2016, DNATURE BIO LABS began as a functional food and beverage business and is currently developing cell therapies for degenerative nervous system diseases. The company develops and manufactures functional food fit to consumers for each age group, gender, and occupational group.

The company provides functional food and beverage containing ingredients that activate brain function to help prevent dementia and attention deficit hyperactivity disorder or ADHD, and enhances antioxidants and anti-inflammatory agents in order to develop immunity. The company is developing a dementia drug called LMTX, which targets Alzheimer's disease causing Tau protein.

DNATURE BIO LABS is in the process of contracting for the multinational pharmaceutical company TauRx Pharmaceuticals to systematically transfer rights for domestic distribution, intellectual property rights, and clinical licenses of dementia treatment drugs particularly LMTX.

## Funding rounds

- Series A, Jul 29, 2021, $3M — ROI Investment Partners

## Investors

- ROI Investment Partners (https://capitalatlas.ai/funds/roi-investment-partners) — Series A